United States securities and exchange commission logo





                            September 10, 2020

       Marcio Souza
       Chief Executive Officer
       Praxis Precision Medicines, Inc.
       One Broadway, 16th Floor
       Cambridge, MA 02142

                                                        Re: Praxis Precision
Medicines, Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted August
28, 2020
                                                            CIK No. 0001689548

       Dear Mr. Souza:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Draft Registration Statement on Form S-1 submitted August 28, 2020

       Business
       License Agreement with RogCon, page 157

   1.                                                   We note your response
to our prior comment 10 and your revisions on page 158. We
                                                        reissue our prior
comment 10 in part. Please expand your disclosure to specify the
                                                        triggers for the
payments referenced. For example, disclose when the profit sharing and
                                                        contingent payments
become payable.
 Marcio Souza
Praxis Precision Medicines, Inc.
September 10, 2020
Page 2
Ionis Collaboration Agreement, page 158

2.    We note your response to comment 11. Please expand your disclosure to
include the
      aggregate potential development milestones and other related conditional
payments
      related to an option exercise.
       You may contact Gary Newberry at (202) 551-3761 or Kate Tillan at (202)
551-3604 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Courtney Lindsay at (202) 551-7237 or Christine Westbrook at (202)
551-5019 with any
other questions.



                                                          Sincerely,
FirstName LastNameMarcio Souza
                                                          Division of
Corporation Finance
Comapany NamePraxis Precision Medicines, Inc.
                                                          Office of Life
Sciences
September 10, 2020 Page 2
cc:       William D. Collins, Esq.
FirstName LastName